News

Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

In the results of this final analysis, the hidradenitis suppurativa drug was found to be well tolerated in patients regardless of either differing demographics or clinical characteristics.

The goal is to address the desaturation drop in oxygen as well as well as treating the arousal effect in the brain, Dr. Lambarca Trocios says.

Sleep fragmentation in obstructive sleep apnea is measured by the number of EEG arousals per hour of sleep but new data from SLEEP 2023 dive deeper into the intensity of arousals.

The results of the study presented at SLEEP 2023 were statistically significant, but not clinically meaningful.

The study stresses the need for better communication with patients and the impact of stress on both the rheumatic disease and mental health.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

Results emphasized the challenges faced in accessing care and the impact on mental health for patients with rheumatic diseases.

There is a need for more large scale studies focusing on treatment adherence for sleep apnea in minority communities.

The IBAT inhibitor will receive an FDA decision by next week. Ovchinsky reviews its supporting data for benefitting patient pruritus, sleep, and liver bile acid levels.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

The higher severity of obstructive sleep apnea is associated with an increased risk of dementia, according to data from SLEEP 2023.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

This research supports the notion that brain morphology may be related to acceleration in the aging process for middle-aged and older-aged adults who have a long history of type 1 diabetes.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

A modification of DAS28 was shown to more accurately represent disease activity in patients with rheumatoid arthritis and concomitant fibromyalgia.

An analysis in Denmark observed increased adherence and persistence in latanoprost users who switched between different latanoprost formulations.

Young adults with psychiatric and behavioral disorders are more likely to experience a decline in sleep intensity and sleep depth more dramatically after adolescence.

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

Patients with rheumatoid arthritis and high disease activity were more likely to be diagnosed with depression and fibromyalgia when compared with those in remission.

An emerging drug class is proving viable for burdensome symptoms, as well as liver failure, in pediatric patients with the rare inherited disease.

Pediatric sleep conditions remain understudied.

For this interview segment, Dr. Arkin discussed the biggest points she hopes dermatologists will take away from National Scleroderma Awareness Month this year.

Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.

With a high rate of lost patients, effective treatment is compromised regardless of the success rendered by unattended portable sleep studies, investigators explain.

Risk factors for trouble sleeping identified, including female sex, former smoking, and diabetes, obstructive lung disease, daytime sleepiness, insomnia, nocturia, and/or snorting/gasping/breathing cessation during sleep.

This new research into psoriasis and its systemic effects and comorbidities may be used to identify the mechanisms which affect skin inflammation in a single area and effects on other organs.